Aspire Biopharma Holdings, Inc. 8-K

What Happened
Aspire Biopharma Holdings, Inc. filed an 8-K (Item 8.01) to clarify the terms of its public warrants trading under the symbol "ASPBW." The warrants were originally issued on February 23, 2022 in connection with the IPO of its predecessor, Power Up Acquisition Corp., with an initial exercise price of $11.50 per share (subject to adjustments). Following a 1-for-30 reverse split on January 16, 2026 and a 1-for-40 reverse split on May 11, 2026, the exercise price has been adjusted to $13,800 per share and the conversion ratio is now 1,200 warrants to purchase one share of common stock.

Key Details

• Issuance: Warrants issued Feb 23, 2022 in connection with Power Up Acquisition Corp. IPO.
• Original terms: Initial exercise price was $11.50 per share (subject to adjustments).
• Reverse splits: 1-for-30 on Jan 16, 2026; 1-for-40 on May 11, 2026 (combined consolidation factor = 1,200).
• New terms: Exercise price = $13,800 per share; ratio = 1,200 warrants required to buy one share. Symbol: ASPBW.

Why It Matters
This filing formally communicates the adjusted exercise price and warrant-to-share ratio after the company’s two reverse stock splits. Warrant holders and potential investors should note the new exercise economics and the large consolidation factor (1,200:1) when evaluating the warrants' value or deciding whether to exercise, trade, or hold ASPBW.